Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Hormone. Princess Margaret Cancer Center, Toronto, ON, Canada



Survival: 21.2 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
Hormone
   
Drugs:
Country: Canada
   
City/State/Province: Toronto, ON
   
Hospital: Princess Margaret Cancer Center
   
Journal: Link
   
Date: 7/2013

Description:
Patients:
This phase 3 study involved metastatic castration-resistant prostate cancer patients who had not received prior chemotherapy and who were divided into two separate treatment groups. Each group consisted of 612 patients; no median age information was provided.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel, the steroid prednisone (anti-inflammatory), and the biologic therapy agent aflibercept (growth factor receptor inhibitor that interferes with tumor blood supply).

Group B patients were treated with docetaxel, prednisone, and a placebo.

Toxicities:
Treatment-related deaths due to infection, heart attack, respiratory problems, and gastrointestinal bleeding were reported for group A. Grade 3-4 diarrhea and nausea/vomiting were also reported.

In group B, treatment-related deaths due to infection, heart attack, respiratory problems, and gastrointestinal bleeding were reported. Grade 3-4 diarrhea, vascular disorders, and fatigue were also reported.

Results:
The median overall survival times for groups A and B were 22.1 and 21.2 months, respectively.

Support:
This study was supported by Sanofi and Regeneron.

Correspondence: Dr. Ian Tannock; email: ian.tannock@uhn.ca

E-mail to a Friend Email Physician More Information